Purple Biotech partners with Converge Bio AI to accelerate tri-specific antibody development
Purple Biotech is collaborating with Converge Bio to integrate proprietary generative AI into its tri-specific antibody platform, aiming to reduce discovery timelines and improve candidate quality. The deal leverages Converge’s 40 completed AI programs to broaden Purple’s CAPTN-3 pipeline against solid tumor targets including 5T4 and TROP2.
1. Collaboration Overview
Purple Biotech announced a collaboration with Converge Bio to integrate generative AI into its CAPTN-3 tri-specific antibody platform, leveraging Converge’s proprietary AI to design and optimize novel oncology candidates with improved functional and physicochemical properties.
2. AI-Driven Development Strategy
Converge Bio’s AI platform, validated across more than 40 partner programs, combines large-scale biological data with predictive modeling and iterative learning to significantly shorten discovery timelines while enhancing molecule quality and developability profiles.
3. Pipeline Impact and Next Steps
AI-driven insights will be applied to develop masked tri-specific antibodies targeting tumor-associated antigens, including lead candidates IM1240 (5T4) and IM1305 (TROP2), with the goal of expanding Purple Biotech’s preclinical pipeline and accelerating progression toward clinical evaluation.